# Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN)

> **NCT04146896** · PHASE2 · COMPLETED · sponsor: **Aptinyx** · enrollment: 228 (actual)

## Conditions studied

- Diabetic Peripheral Neuropathic Pain

## Interventions

- **DRUG:** NYX-2925 50 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04146896
- **Lead sponsor:** Aptinyx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-12
- **Primary completion:** 2022-02-23
- **Final completion:** 2022-02-23
- **Target enrollment:** 228 (ACTUAL)
- **Last updated:** 2023-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04146896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04146896, "Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04146896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*